Gilead Sciences - 31 Year Stock Price History | GILD
Historical daily share price chart and data for Gilead Sciences since 1992 adjusted for splits. The latest closing stock price for Gilead Sciences as of February 03, 2023 is 84.50.
- The all-time high Gilead Sciences stock closing price was 94.64 on June 23, 2015.
- The Gilead Sciences 52-week high stock price is 89.74, which is 6.2% above the current share price.
- The Gilead Sciences 52-week low stock price is 57.16, which is 32.4% below the current share price.
- The average Gilead Sciences stock price for the last 52 weeks is 68.42.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Gilead Sciences Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2023 |
84.6900 |
85.3900 |
88.0800 |
81.3900 |
84.5000 |
-1.57% |
| 2022 |
65.5461 |
69.4286 |
88.7372 |
55.4052 |
85.8500 |
23.60% |
| 2021 |
63.2453 |
55.1419 |
70.4426 |
55.0410 |
69.4573 |
29.96% |
| 2020 |
61.6163 |
57.4547 |
74.7209 |
51.9678 |
53.4448 |
-6.62% |
| 2019 |
56.6198 |
53.8075 |
59.9766 |
52.9861 |
57.2345 |
7.88% |
| 2018 |
61.4537 |
60.9176 |
73.0025 |
51.3478 |
53.0526 |
-9.92% |
| 2017 |
58.5313 |
59.2312 |
69.3387 |
51.6053 |
58.8953 |
2.97% |
| 2016 |
65.8266 |
76.5272 |
80.2487 |
56.9567 |
57.1946 |
-27.61% |
| 2015 |
82.4854 |
73.2342 |
94.6440 |
73.2342 |
79.0102 |
8.63% |
| 2014 |
69.1205 |
58.0334 |
88.1342 |
50.5255 |
72.7327 |
25.51% |
| 2013 |
43.2573 |
28.9588 |
58.0257 |
28.9164 |
57.9485 |
104.49% |
| 2012 |
21.8063 |
16.1500 |
29.4526 |
16.1500 |
28.3377 |
79.45% |
| 2011 |
15.4045 |
14.1129 |
16.6708 |
13.6345 |
15.7912 |
12.94% |
| 2010 |
15.1509 |
16.7055 |
19.0782 |
12.2803 |
13.9817 |
-16.25% |
| 2009 |
17.7917 |
20.1315 |
20.3707 |
15.9879 |
16.6939 |
-15.39% |
| 2008 |
18.9758 |
17.4926 |
22.0297 |
14.4563 |
19.7303 |
11.15% |
| 2007 |
15.2703 |
12.1819 |
18.4185 |
12.1009 |
17.7511 |
41.72% |
| 2006 |
11.9428 |
10.5519 |
13.4551 |
10.3686 |
12.5253 |
23.51% |
| 2005 |
8.1551 |
6.6996 |
10.7313 |
5.9878 |
10.1410 |
50.24% |
| 2004 |
6.2065 |
5.5962 |
7.5310 |
4.9924 |
6.7497 |
20.08% |
| 2003 |
4.9661 |
3.3652 |
6.7507 |
3.1154 |
5.6212 |
71.41% |
| 2002 |
3.2847 |
2.9625 |
3.8301 |
2.5608 |
3.2794 |
3.47% |
| 2001 |
2.4182 |
1.7875 |
3.4824 |
1.3036 |
3.1694 |
58.48% |
| 2000 |
1.8167 |
1.3578 |
2.8019 |
1.0475 |
1.9999 |
53.23% |
| 1999 |
1.2872 |
0.9585 |
2.2276 |
0.8620 |
1.3052 |
31.83% |
| 1998 |
0.7691 |
0.9194 |
1.0429 |
0.4401 |
0.9901 |
7.35% |
| 1997 |
0.7560 |
0.5908 |
1.1123 |
0.5216 |
0.9223 |
53.00% |
| 1996 |
0.6838 |
0.7866 |
0.9826 |
0.4160 |
0.6028 |
-21.88% |
| 1995 |
0.4445 |
0.2261 |
0.7776 |
0.2261 |
0.7716 |
236.80% |
| 1994 |
0.2425 |
0.2894 |
0.3376 |
0.1688 |
0.2291 |
-20.84% |
| 1993 |
0.3567 |
0.4401 |
0.4613 |
0.2592 |
0.2894 |
-37.66% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$105.984B |
$27.281B |
|
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
|
